Initial endocrine therapy tops chemotherapy for HR+/HER2- metastatic breast cancer


  • Heather Mason
  • Univadis Medical News
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

A population-based study of patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer showed that initial treatment with endocrine therapy (ET) improves survival, compared to initial treatment with chemotherapy (CT).

The retrospective analysis, published in British Journal of Cancer, used data from the Côte d’Or Breast and Gynaecological Cancer Registry and included 557 patients, of which 280 received initial treatment with ET and 277 received initial treatment with CT. Primary and secondary outcomes were progression-free survival (PFS) and overall survival (OS), respectively.

There were no statistical differences between the two groups concerning primary tumour characteristics (diagnostic year, histological subtype, hormone receptor status, and node status).

Both survival outcomes improved significantly in patients initially treated with ET (HR 0.83; 95% CI 0.69-0.99) when compared to patients who received initial CT (HR 0.71; 95% CI 0.58-0.86).

This study shows that treating patients with HR+/HER2- metastatic breast cancer with initial ET could provide a survival advantage in comparison with initial CT, thus supporting the international guidelines that advocate the use of ET as the preferred option for HR+/HER2- metastatic breast cancer.